Amyloid and tau‐PET in early‐onset AD: Baseline data from the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)
Alzheimer's & Dementia · 2023-11 · 19 (S9)
DOI: 10.1002/alz.13453 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Alzheimer's & Dementia, online erschienen am 10.09.2023. Verfasst von Hanna Cho und 50 weiteren Autor:innen. Beteiligte Einrichtung: Memory and Aging Center, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, California, USA. Hauptthemen laut MEDLINE: Alzheimer Disease, Cognitive Dysfunction. Die Arbeit wurde bisher 55-mal zitiert (Crossref) und nennt 75 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NINDS NIH HHS, NIA NIH HHS, Alzheimer's Association.
Themen: Demenz
Abstract (Originalsprache)
INTRODUCTION We aimed to describe baseline amyloid‐beta (Aβ) and tau‐positron emission tomograrphy (PET) from Longitudinal Early‐onset Alzheimer's Disease Study (LEADS), a prospective multi‐site observational study of sporadic early‐onset Alzheimer's disease (EOAD). METHODS We analyzed baseline [18F]Florbetaben (Aβ) and [18F]Flortaucipir (tau)‐PET from cognitively impaired participants with a clinical diagnosis of mild cognitive impairment (MCI) or AD dementia aged < 65 years. Florbetaben scans were used to distinguish cognitively impaired participants with EOAD (Aβ+) from EOnonAD (Aβ−) based on the combination of visual read by expert reader and image quantification. RESULTS 243/321 (75.7%) of participants were assigned to the EOAD group based on amyloid‐PET; 231 (95.1%) of them were tau‐PET positive (A+T+). Tau‐PET signal was elevated across cortical regions with a parietal‐predominant pattern, and higher burden was observed in younger and female EOAD participants. DISCUSSION LEADS data emphasizes the importance of biomarkers to enhance diagnostic accuracy in EOAD. The advanced tau‐PET binding at baseline might have implications for therapeutic strategies in patients with EOAD. HIGHLIGHTS 72% of patients with clinical EOAD were positive on both amyloid‐ and tau‐PET. Amyloid‐positive patients with EOAD had high tau‐PET signal across cortical regions. In EOAD, tau‐PET mediated the relationship between amyloid‐PET and MMSE. Among EOAD patients, younger onset and female sex were associated with higher tau‐PET.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Memory and Aging Center, UCSF Weill Institute for Neurosciences, Department of Neurology, University of California, San Francisco, California, USA.
- Department of Neurology, Gangnam Severance Hospital, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Global Brain Health Institute, University of California, San Francisco, California, USA.
- Department of Neurology, Indiana University School of Medicine, Indianapolis, Indiana, USA.
- Department of Radiology and Imaging Sciences, Center for Neuroimaging, Indiana University School of Medicine Indianapolis, Indianapolis, Indiana, USA.
- Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Förderung
- NINDS NIH HHS
- NIA NIH HHS
- Alzheimer's Association
Zitieren
APA
Cho, H., Mundada, N. S., Apostolova, L. G., Carrillo, M. C., Shankar, R., Amuiri, A. N., Zeltzer, E., Windon, C. C., Soleimani-Meigooni, D. N., Tanner, J. A., Heath, C. L., Lesman-Segev, O. H., Aisen, P., Eloyan, A., Lee, H. S., Hammers, D. B., Kirby, K., Dage, J. L., Fagan, A., …, & LEADS Consortium (2023). Amyloid and tau‐PET in early‐onset AD: Baseline data from the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS). Alzheimer's & Dementia, 19(S9). https://doi.org/10.1002/alz.13453
Vancouver
Cho H, Mundada NS, Apostolova LG, Carrillo MC, Shankar R, Amuiri AN, et al. Amyloid and tau‐PET in early‐onset AD: Baseline data from the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS). Alzheimer's & Dementia. 2023;19(S9). doi:10.1002/alz.13453
BibTeX
@article{Cho2023,
author = {Cho, Hanna and Mundada, Nidhi S and Apostolova, Liana G and Carrillo, Maria C and Shankar, Ranjani and Amuiri, Alinda N and Zeltzer, Ehud and Windon, Charles C and Soleimani-Meigooni, David N and Tanner, Jeremy A and Heath, Courtney Lawhn and Lesman-Segev, Orit H and Aisen, Paul and Eloyan, Ani and Lee, Hye Sun and Hammers, Dustin B and Kirby, Kala and Dage, Jeffrey L and Fagan, Anne and Foroud, Tatiana and Grinberg, Lea T and Jack, Clifford R and Kramer, Joel and Kukull, Walter A and Murray, Melissa E and Nudelman, Kelly and Toga, Arthur and Vemuri, Prashanthi and Atri, Alireza and Day, Gregory S and Duara, Ranjan and Graff-Radford, Neill R and Honig, Lawrence S and Jones, David T and Masdeu, Joseph and Mendez, Mario and Musiek, Erik and Onyike, Chiadi U and Riddle, Meghan and Rogalski, Emily J and Salloway, Stephen and Sha, Sharon and Turner, Raymond Scott and Wingo, Thomas S and Wolk, David A and Koeppe, Robert and Iaccarino, Leonardo and Dickerson, Bradford C and La Joie, Renaud and Rabinovici, Gil D and LEADS Consortium, LEADS Consortium},
title = {Amyloid and tau‐PET in early‐onset AD: Baseline data from the Longitudinal Early‐onset Alzheimer's Disease Study (LEADS)},
journal = {Alzheimer's & Dementia},
year = {2023},
volume = {19},
number = {S9},
doi = {10.1002/alz.13453}
}
EUVIMED